Credit Suisse Reiterates Intercept's Lofty $200 Price Target; Ocaliva Will Be A 'Surprisingly Solid Launch'
May 31, 2016 at 15:37 PM EDT
Credit Suisse's Alethia Young reiterated her Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ: ICPT) with a price target of ...